22 09, 2026

New evidence on variability of plasma miR-122 published with contribution of TAmiRNA

2026-09-22T10:58:24+02:00September 22nd, 2026|biomarker, circulating miRNAs, DILI, drug-induced liver injury, microRNA services, miND, miND spike ins, RNA, small RNA-sequencing, smallRNA, TransBioLine|0 Comments

A short communication published in the British Journal of Clinical Pharmacology re-evaluates the inter- and intra-individual variability of circulating miR-122 in healthy volunteers, using small RNA sequencing generated on TAmiRNA's miND workflow (Javid et al., 2026, doi:10.1002/bcp.70836). Background MicroRNA-122 (miR-122) is a liver-enriched circulating microRNA and one of the most extensively studied candidate biomarkers for drug-induced liver injury (DILI). A 2019 evaluation by Church et al. reported substantial inter- and intra-individual variability of miR-122 in healthy volunteers, which raised questions about its use as a diagnostic biomarker. The present study, conducted within the IMI2 TransBioLine consortium, set out to re-examine this variability in new, independent cohorts. Study and findings Plasma samples from 280 healthy volunteers were collected [...]

8 09, 2026

TAmiRNA Joins Six European RNA Specialists to Launch the European RNA Alliance

2026-09-10T10:01:04+02:00September 8th, 2026|biomarker, circulating miRNAs, ERA, European RNA Alliance, EV characterization, exosomes, extracellular vesicle, microRNA services, miND, miND spike ins, RNA, small RNA-sequencing, smallRNA|1 Comment

As a founding member of ERA, TAmiRNA positions itself as the innovative driving force behind RNA biomarker development in Europe — combining novel biomarker products with premier research services in cell-free RNA and EV/exosome analysis. Vienna, Austria — September 8, 2026 TAmiRNA is proud to announce that it has joined six other independent European RNA companies — Anemocyte, Genevia Technologies, Immagina Biotechnology, Lexogen, MultiplexDX, and siTOOLS Biotech — as a founding member of the European RNA Alliance (ERA), a new strategic alliance launched today to strengthen Europe's position in high-quality RNA technologies. RNA technologies are increasingly central to modern medicine — diagnostics, disease monitoring, prophylaxis, therapeutics, and personalized treatment. Yet Europe's considerable expertise in this space is [...]

1 09, 2026

TAmiRNA is a Silver Sponsor at the D-A-CH EV Meeting 2026 in Erlangen

2026-09-01T10:20:37+02:00September 1st, 2026|biomarker, circulating miRNAs, Conference, EV characterization, exosomes, extracellular vesicle, microRNA services, miND, miND spike ins, RNA, small RNA-sequencing, smallRNA|Comments Off on TAmiRNA is a Silver Sponsor at the D-A-CH EV Meeting 2026 in Erlangen

From September 28–30, 2026, the D-A-CH EV Meeting 2026 will take place at the Hörsaalzentrum of the Medical Faculty, University Hospital Erlangen — the first joint annual meeting of the German, Austrian and Swiss societies for extracellular vesicles (GSEV, ASEV and SwissEV). Under the motto "Extracellular Vesicles: Communication Across Barriers," around 300 to 350 international scientists from the EV field will gather in Erlangen. The three-day programme covers the full breadth of EV research: from the fundamentals of EV biology, purification and characterization, to methodological advances, microbial EVs, clinical translation, reproducibility and open questions in EV research, as well as novel EV sources and emerging concepts. Keynote lectures, selected abstracts, poster sessions, roundtable discussions and industry presentations [...]

21 09, 2023

Unique miRNome and transcriptome profiles underlie microvascular heterogeneity in mouse kidney

2023-09-21T11:12:47+02:00September 21st, 2023|biomarker, biomarkers, LMD, microRNA services, microRNAs, microstructure, NGS, Vivomicx|Comments Off on Unique miRNome and transcriptome profiles underlie microvascular heterogeneity in mouse kidney

We want to draw your attention to our latest publication which appeared in American Journal of Physiology-Renal Physiology. We could show that laser microdissection combined with (small) RNA sequencing revealed renal microvascular compartment-specific miRNA and mRNA expression profiles. Unique miRNome and transcriptome profiles underlie microvascular heterogeneity in mouse kidney Luxen M, Zwiers PJ, Meester F et al. Am J Physiol Renal Physiol. 2023 Sep 1;325(3):F299-F316. doi: 10.1152/ajprenal.00005.2023. Epub 2023 Jul 6. TAmiRNA and Dutch company Vivomicx have combined their respective technologies of high sensitivity gene expression profiling (RT-qPCR and smallRNAseq/RNAseq) and laser microdissection to enable cell-type specific and space-resolved RNA expression analysis in complex tissues. Click here to learn more about this service

26 05, 2022

hepatomiR kit

2023-03-10T10:14:05+01:00May 26th, 2022|biomarkers, hepatomiR kit, Liver disease, microRNA|Comments Off on hepatomiR kit

TAmiRNA has launched its latest hepatomiR® CE-IVD testing kit that can measure levels of three important liver-enriched microRNAs (liver miRNAs) in human blood to determine a patient’s liver function. TAmiRNA’s microRNA-based hepatomiR® kit is worldwide the first approved CE-IVD test to measure microRNA liver biomarkers in human plasma. The new microRNA-based hepatomiR® technology represents a milestone previously restricted to research use only (RUO) testing. click here for more Information on the hepatomiR-kit

2 03, 2022

miRNA NGS Discovery pipeline – miND

2023-03-10T10:13:34+01:00March 2nd, 2022|biomarkers, microRNA, NGS|Comments Off on miRNA NGS Discovery pipeline – miND

TAmiRNA present microRNA Next-Generation-Sequencing Discovery Assay (miND), a novel panel of exogenous small RNA spike-in controls that enables quality control and absolute quantitation of NGS data. Eager to learn more - have a look at our two new publications! click here for more Information on the novel wet-lab small RNA-seq workflow and here for more insights into the bioinformatic pipeline

9 04, 2021

TAmiRNA shares microRNA biomarker insights at FIDELIO training webinar

2023-03-10T10:19:36+01:00April 9th, 2021|aging, biomarker, biomarkers, bone diseases, bone fracture risk assessment, diabetes, microRNAs, microstructure, osteoporosis, Personalized medicine, type 2 diabetes mellitus|Comments Off on TAmiRNA shares microRNA biomarker insights at FIDELIO training webinar

TAmiRNA is a key partner in the EU-funded Innovative Training Network FIDELIO, which aims to train the next generation of scientists in tackling the challenges of bone fragility in diabetic patients. The  webinar "MicroRNAs: small RNAs with big potential as biomarkers and drug targets in bone diseases" is a one-hour session hosted by TAmiRNA founder and CEO Dr. Matthias Hackl. He show how microRNAs control gene expression in virtually all human cells and that miRNA expression changes during the onset and progression of (bone) disorders enabling applications as biomarkers and drug targets. He introduce the biological and methodical basics of microRNA research and discuss diagnostic and therapeutic applications of microRNAs in bone disease. [...]

19 01, 2021

Circulating miRNAs in bone health and disease

2023-03-10T11:38:55+01:00January 19th, 2021|aging, biomarker, biomarkers, bone diseases, bone fracture risk assessment, microRNAs, microstructure, osteoporosis, Personalized medicine|Comments Off on Circulating miRNAs in bone health and disease

We want to draw your attention to our latest review which appeared in the special issue on miRNAs in Bone Research in Bone. In this review, we summarize important molecular basics of microRNA function and release and provide recommendations for best (pre-)analytical practices and documentation standards for circulating microRNA research required for generating high quality data and ensuring reproducibility of results. We review how the genesis of bone-derived circulating microRNAs via release from osteoblasts and osteoclasts could contribute to the communication between these cells and summarize evidence from clinical research studies that have investigated the clinical utility of microRNAs as biomarkers in musculoskeletal disorders. While previous reviews have mainly focused on diagnosis of primary osteoporosis, we have [...]

24 11, 2020

microRNA-146a controls age-related bone loss

2023-03-10T10:21:20+01:00November 24th, 2020|aging, biomarker, biomarkers, bone diseases, bone fracture risk assessment, microRNAs, microstructure, osteoporosis, Personalized medicine|Comments Off on microRNA-146a controls age-related bone loss

We want to draw your attention to the latest publication in cooperation with TAmiRNA. The study identifies a novel and unexpected role of miR‐146a in bone homeostasis. miR‐146a increases with age and acts as an epigenetic molecular switch terminating bone accrual, leading to bone loss during aging by downregulating bone anabolic Wnt signaling. Conversely, loss of miR‐146a leads to continuous bone accrual during aging as a result of unrestricted bone anabolism and intact Wnt signaling. Therefore, miR‐146a crucially controls the temporal facet of bone homeostasis. "microRNA-146a controls age-related bone loss" Saferding V, Hofmann M, Brunner JS, et al. Aging Cell. 2020 Nov;19(11):e13244. doi: 10.1111/acel.13244. click here to read the story

6 10, 2020

MedUni Wien “Researcher of the Month” Oktober 2020

2023-03-10T10:53:18+01:00October 6th, 2020|biomarker, Liver disease, microRNAs, Personalized medicine|Comments Off on MedUni Wien “Researcher of the Month” Oktober 2020

We want to congratulate Dr. Patrick Starlinger to his award “Researcher of the Month” for his work in cooperation with TAmiRNA GmbH, in Hepatology. "Predicting Postoperative Liver Dysfunction Based on Blood Derived MicroRNA Signatures." Hepatology. 2019 Jun;69(6):2636-2651. Click here for more information on TAmiRNA services Click here to read the story

Go to Top